S1P/S1PR 

 57 Products   57 Products   190 Diseases   10960 News 


«12...678910111213141516...105106»
  • ||||||||||  fingolimod / Generic mfg.
    Trial completion date:  Safety and Effectiveness of Generic Fingolimod (Sphingomod (clinicaltrials.gov) -  Mar 5, 2024   
    P=N/A,  N=30, Active, not recruiting, 
    Even in immunosuppressive patients, seroconversion is satisfactory. Trial completion date: Oct 2023 --> May 2024
  • ||||||||||  teriflunomide / Generic mfg., fingolimod / Generic mfg.
    Preclinical, Journal, Immunomodulating:  Clinically approved immunomodulators ameliorate behavioral changes in a mouse model of hereditary spastic paraplegia type 11. (Pubmed Central) -  Mar 4, 2024   
    Translating this into a clinically applicable approach, we show that treatment with the established immunomodulators fingolimod or teriflunomide significantly attenuates distinct behavioral abnormalities, with the most striking effect on social behavior. This study links neuroinflammation to behavioral abnormalities in a mouse model of SPG11 and may thus pave the way for using immunomodulators as a treatment approach for SPG11 and possibly other complicated forms of HSP with neuropsychological involvement.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty
    Review, Journal:  Knowledge domain and trend of disease-modifying therapies for multiple sclerosis: A study based on CiteSpace. (Pubmed Central) -  Mar 4, 2024   
    Current research hotspots and trends in DMTs in multiple sclerosis focus on the effectiveness of different DMTs drugs in treating patients with MS and how to optimise treatment strategies. In the context of the COVID-19 pandemic, the correlation between MS and COVID-19 infection and the method to manage and address the adverse effects of DMTs on multiple sclerosis patients is also future research trends.
  • ||||||||||  fingolimod / Generic mfg.
    Journal:  Managing pediatric-onset multiple sclerosis in an austere setting: A case report. (Pubmed Central) -  Mar 1, 2024   
    As a result, the immediate flare was accurately diagnosed and treated with steroids, the patient was started on Fingolimod, and an emergency management plan for future flares was constructed. This case illustrates the nuances of both the acute and chronic management of multiple sclerosis in a resource-limited setting and how a combination of synchronous and asynchronous telemedicine was able to achieve a satisfactory treatment plan.
  • ||||||||||  Zeposia (ozanimod) / BMS
    Enrollment open, Trial completion date, Trial primary completion date:  An Examination of Cognitive Fatigue Using Functional Neuroimaging (clinicaltrials.gov) -  Mar 1, 2024   
    P=N/A,  N=60, Recruiting, 
    This case illustrates the nuances of both the acute and chronic management of multiple sclerosis in a resource-limited setting and how a combination of synchronous and asynchronous telemedicine was able to achieve a satisfactory treatment plan. Not yet recruiting --> Recruiting | Trial completion date: Aug 2023 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2024
  • ||||||||||  fingolimod / Generic mfg.
    Journal:  Quantiferon Monitor Testing Sheds Light on Immune System Disparities between Multiple Sclerosis Patients and Healthy Individuals. (Pubmed Central) -  Feb 28, 2024   
    This study, conducted from August 2019 to June 2023, included 280 participants: 98 RRMS patients treated with fingolimod (fMS), 96 untreated patients with progressive MS (pMS), and 86 healthy controls (HC)...Statistical analysis indicated significant differences in the interleukin levels between groups, with IL-1ra and age as key predictors in differentiating HC from pMS and IL-1ra, IL-1?, age, and EDSS in distinguishing pMS from fMS. These findings suggest cytokines' potential as biomarkers in MS progression and treatment response.
  • ||||||||||  fingolimod / Generic mfg.
    Intrapulmonary T Cells Are Sufficient for Schistosoma-induced Pulmonary Hypertension (San Diego Convention Center, Area D (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_924;    
    Blocking T cell migration into the lungs was insufficient to suppress PH followingIV Schistosoma egg challenge. Pre-positioned CD4 T cells in the lung may be sufficient tocause Type 2 inflammation and PH.
  • ||||||||||  fingolimod / Generic mfg.
    Preclinical, Journal:  Microvascular Network Remodeling in the Ischemic Mouse Brain Defined by Light Sheet Microscopy. (Pubmed Central) -  Feb 15, 2024   
    We also examined the effect of a clinically applicable S1P (sphingosine-1-phosphate) analog, FTY720 (fingolimod), on microvascular network remodeling...Utilizing light sheet microscopy together with automated image analysis, we characterized microvascular remodeling post-ischemia in unprecedented detail. This technology will significantly advance our understanding of microvascular restorative processes and pave the way for novel treatment developments in the stroke field.
  • ||||||||||  mocravimod (KRP-203) / Priothera
    MOCRAVIMOD FAVOURABLY AFFECTS OVERALL SURVIVAL IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (Hall 3 North) -  Feb 14, 2024 - Abstract #EBMT2024EBMT_2012;    
    P1, P3
    This post hoc analysis demonstrated an OS benefit for pts with hematologic diseases receiving MOC as add-on treatment to allo-HCT in comparison to a matched real-world cohort undergoing allo-HCT without MOC. These data support the development of MOC as an adjunctive and maintenance treatment to allo-HCT, which is currently evaluated in the Phase III MO-TRANS trial, a worldwide double-blind trial investigating the GvL effect of MOC translating into prolonged relapse-free-survival and OS in AML pts undergoing allo-HCT (NCT05429632)
  • ||||||||||  Zeposia (ozanimod) / BMS
    Journal:  Concise Commentary: Ozanimod in Real Life-Plus  (Pubmed Central) -  Feb 14, 2024   
    Taken together, MOC can be co-administered with CYP3A4 inhibitors such as azoles without dosage adjustments in allo-HCT patients. No abstract available
  • ||||||||||  fingolimod / Generic mfg.
    Review, Journal:  Metabolism, fibrosis, and apoptosis: The effect of lipids and their derivatives on keloid formation. (Pubmed Central) -  Feb 14, 2024   
    Both Vitamin D and hexadecylphosphorylcholine (HePC) showed potential antifibrotic and antiproliferative properties, suggesting their utility in keloid management. While keloids remain a prevalent concern in clinical practice, this study underscores the promising potential of targeting specific lipid molecules for the advancement of keloid therapeutic strategies.
  • ||||||||||  icanbelimod (CBP-307) / Suzhou Connect Biopharma, Mayzent (siponimod) / Novartis
    Journal:  Fine-tuning activation specificity of G-protein-coupled receptors via automated path searching. (Pubmed Central) -  Feb 12, 2024   
    BRET assays confirmed that both chiral forms activate S1PR1 at nanomolar concentration, 1 to 2 orders of magnitude less than those for S1PR3/5. Collectively, these results signify the promise of our approach in fine agonist design for G-protein-coupled receptors.
  • ||||||||||  Mayzent (siponimod) / Novartis
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (clinicaltrials.gov) -  Feb 11, 2024   
    P=N/A,  N=451, Completed, 
    Collectively, these results signify the promise of our approach in fine agonist design for G-protein-coupled receptors. Recruiting --> Completed | N=330 --> 451 | Trial completion date: Feb 2025 --> Aug 2023 | Trial primary completion date: Feb 2025 --> Aug 2023
  • ||||||||||  fingolimod / Generic mfg.
    Review, Journal:  Therapeutic Potential of Fingolimod in Diabetes Mellitus and Its Chronic Complications. (Pubmed Central) -  Feb 6, 2024   
    Several studies have shown that it has beneficial effects on the improvement of diabetes and its chronic complications. This paper reviews the therapeutic potential of Fingolimod in diabetes and its chronic complications, aiming to further guide future treatment strategies.
  • ||||||||||  Journal:  A comparison of clinical, utilization, and cost outcomes between oral treatments for multiple sclerosis. (Pubmed Central) -  Feb 3, 2024   
    To compare MS outcomes, health care resource utilization, and relative costs across treatment with dimethyl fumarate (DMF), fingolimod (FG), or teriflunomide (TERI) among Medicare Advantage Prescription Drug (MAPD) plan and commercially insured beneficiaries...FG had the lowest impatient stays and emergency department visits of the 3 groups. Patients with MS initiated on FG used fewer health care resources and experienced lower ARR compared with patients on DMF and TERI.